Skip to main content
Fig. 6 | BMC Immunology

Fig. 6

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Fig. 6

Evolution of VEGF-specific IgG antibodies and VEGF/VEGFR2 blockade in patients submitted to long-term re-immunizations. Samples, taken at different time points, came from twelve patients (depicted by their trial code name) with an overall survival longer than 45 weeks (approximately 1 year). Antibody titers and VEGF/VEGFR2 blockade percentages are shown as black dots and red bars, respectively. Week 0 is pre-vaccination and week 13 is one week after finishing the trial vaccinations. Cut-off values that define the positivity for IgG antibodies (black discontinued line) and VEGF/VEGFR2 blockade (red discontinued line) are shown for each patient

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us